Aytu BioPharma Q4 revenue beats analyst estimates on EXXUA sales
AYTU•Outlook
- Company expects EXXUA launch momentum to continue, with evolving prescribing and payer patterns
- Company aims to build toward more consistent positive adjusted EBITDA levels during fiscal 2027
- ADHD and Pediatric portfolios expected to provide financial stability to support EXXUA investment
Overview
- US pharmaceutical firm's fiscal Q4 revenue rose 6.4%, beating analyst expectations
- Company reported near break-even net loss for the quarter, improving from prior year
Result drivers
- EXXUA launch - Q4 revenue was driven by the first full quarter of EXXUA sales, with management citing growing prescription volume and broadening adoption
- ADHD portfolio - Sequential improvement in ADHD Portfolio revenue was attributed to higher units, improved gross-to-net economics, and stable performance across existing brands, despite generic competition
- Pediatric portfolio - Q4 Pediatric Portfolio revenue increased from the prior quarter as product availability normalized following a supply disruption
